Drug Transporter (DT) Information

General Information of DT
DT ID DTD0015
Gene Name ABCC4
Protein Name Multidrug resistance-associated protein 4
Gene ID
10257
UniProt ID
O15439
TCDB ID
3.A.1.208.7
3D Structure

Modelled DT Structure

Method: homology modeling

Template PDB: 5UJ9_A

Identity: 36.634%

Minimized Score: -2733.132 kcal/mol

Detail: Structure Info

Synonyms ABCC4; ATP-binding cassette sub-family C member 4; MOAT-B; MOATB; MRP/cMOAT-related ABC transporter; MRP4; Multi-specific organic anion transporter B
DT Family ATP-Binding Cassette (ABC) Superfamily
Drug Conjugate Transporter (DCT) Family (ABCC)
Tissue Specificity Widely expressed, with particularly highlevels in prostate, but is barely detectable in liver.
Function This transporter may be an organic anion pump relevant to cellular detoxification.
Disease(s) Acute myeloid leukemia [ICD-11: 2A60]
Colorectal cancer [ICD-11: 2B91]
Erectile dysfunction [ICD-11: HA01]
High blood pressure [ICD-11: BA00]
Human immunodeficiency virus infection [ICD-11: 1C62.Z]
Influenza virus [ICD-11: 1E30-1E32]
Ovarian cancer [ICD-11: 2C73]
Hypercalcemia [ICD-11: 5B91.0]
Seizure [ICD-11: 8A68]
Endogenous Substrate(s) 9-(2-phosphonylmethyoxyethyl)adenine; Cyclic nucleotides; Estradiol 17-beta-D-glucuronides; Leukotrienes; Nucleotide analogues; Prostagland E1; Reduced folates; Bile acids; Cholate; Cholyltaurine; Dehydroepiandrosterone sulfate
Variability Data of This Drug Transporter (DT)

Regulatory Variability Data of This DT (VARIDT 3.0)

(α) Microbiota Influence of This DT
Microbiota Influence (MBI)

(β) Post-translational Modification of This DT
Post-translational Modification (PTM)

(γ) Transcriptional Regulation of This DT
Transcriptional Regulation (TSR)

(δ) Epigenetic Regulation of This DT
Epigenetic Regulation (EGR)

(ε) Exogenous Modulation of This DT
Exogenous Modulation (EGM)

Structural Variability Data of This DT (VARIDT 2.0)

(α) Mutation-induced Structural Variation
Mutation-induced Structural Variation (MSV)

(β) Inter-species Structural Differences
Inter-species Structural Differences (ISD)

(γ) Outward/inward-facing Conformation
Outward/inward-facing Conformation (OIC)

(δ) Xenobiotics-regulated Structural Variability
Xenobiotics-regulated Structural Variability (XSV)

General Variability Data of This DT (VARIDT 1.0)

(α) Genetic Polymorphisms of This DT
Genetic Polymorphisms of This DT (GPD)

(β) Disease-specific Protein Abundances of This DT
Disease-specific Protein Abundances of This DT (DPAD)

(γ) Species- and Tissue-specific DT Abundances
Species/Tissue-specific Protein Abundances of This DT (S/TPAD)
Molecular Transporting Profile of This DT

Full List of Drug(s) Transported by This DT

 Approved Drug

 Click to Show/Hide the Full List of Drug:          28 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Abacavir
 Approved Drug Info Human immunodeficiency virus infection 1C62.Z [1]
Adefovir
 Approved Drug Info Herpes simplex virus infection 1F00 [2]
Alprostadil
 Approved Drug Info Erectile dysfunction HA01 [3]
Cefadroxil
 Approved Drug Info Gram-positive & negative bacteria infections 1A00-1H0Z [4]
Cefazolin
 Approved Drug Info Methicillin-susceptible staphylococcus aureus 1B74.0 [4]
Ceftizoxime
 Approved Drug Info Gram-positive & negative bacteria infections 1A00-1H0Z [4]
Cholic acid
 Approved Drug Info Synthesis disorders 5C52.10 [1]
Ciprofloxacin
 Approved Drug Info Seizure 8A68 [5]
Cladribine
 Approved Drug Info Hairy cell leukemia 2A82.2 [1]
Cyclophosphamide
 Approved Drug Info Lymphomas 2B33.5 [6]
Dehydroepiandrosterone sulfate
 Approved Drug Info Dyspareunia GA12 [7]
Dinoprostone
 Approved Drug Info Medical abortion JA00.1 [3]
Fluorouracil
 Approved Drug Info Stomach cancer 2B72 [8]
Folic acid
 Approved Drug Info Vitamin deficiency 5B55-5B7Z [9]
Ganciclovir
 Approved Drug Info Cytomegalovirus infections 1D82 [1]
Glutathione
 Approved Drug Info Human immunodeficiency virus infection 1C62.Z [10]
Irinotecan
 Approved Drug Info Colorectal cancer 2B91 [11]
Leucovorin
 Approved Drug Info Colorectal cancer 2B91 [9]
Mercaptopurine
 Approved Drug Info Acute lymphoblastic leukemia 2B33.0 [12]
Methotrexate
 Approved Drug Info Leukemia 2A60-2B33 [13]
Olmesartan medoxomil
 Approved Drug Info High blood pressure BA00 [14]
Oseltamivir
 Approved Drug Info Influenza virus 1E30-1E32 [15]
Prasterone
 Approved Drug Info Hypercalcemia 5B91.0 [7]
Sulindac
 Approved Drug Info Rheumatoid arthritis FA20 [16]
Tenofovir
 Approved Drug Info Human immunodeficiency virus infection 1C62.Z [2]
Thioguanine
 Approved Drug Info Acute myeloid leukemia 2A60 [17]
Topotecan
 Approved Drug Info Ovarian cancer 2C73 [18]
Zidovudine
 Approved Drug Info Human immunodeficiency virus infection 1C62.Z [1]

 Clinical Trial Drug

 Click to Show/Hide the Full List of Drug:            5 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Camptothecin
 Phase 3 Drug Info Non-small cell lung cancer 2C25 [1]
Glycocholic acid
 Phase 3 Drug Info Bile acid synthesis defect 5C52.11 [1]
SN-38
 Phase 2 Drug Info Colon cancer 2B90.Z [1]
Rubitecan
 Phase 1/2 Drug Info Ewing's sarcoma 2B52 [1]
Hydroxycamptothecin
 Phase 1 Drug Info Solid tumours 2D4Z [1]

 Phase 3 Drug

 Click to Show/Hide the Full List of Drug:            1 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Quercetin
 Phase 3 Drug Info Coronary artery disease BA6Z [1]

 Withdrawn, Discontinued or Preclinical Drug

 Click to Show/Hide the Full List of Drug:            6 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Aminohippuric acid
 Withdrawn Drug Info Renal function tests MG02 [19]
Resveratrol
 Discontinued in Phase 2 Drug Info Colorectal cancer 2B91 [1]
Azidothymidine monophosphate
 Preclinical Drug Info Cancer 2A00-2F9Z [20]
Glycodeoxycholic acid
 Preclinical Drug Info Asthma CA23 [1]
Prostaglandin f2Alpha
 Preclinical Drug Info Solid tumours 2D4Z [1]
Taurocholic acid
 Terminated Drug Info Type 2 diabetes 5A11 [1]

Endogenous Metabolites (EMs) Handled by This DT

 Endogenous Metabolites (EMs)

 Click to Show/Hide the Full List of EMs:            1 EMs in Total
EM Name PubChem CID Detail Experimental Material Ref
Urate
1175
EM Info Identified using Aldh16a1 knockout mice [21]

Drug-DT Affinity Assessed by Cell Line

 Approved Drug

 Click to Show/Hide the Full List of Drug:          12 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
Alprostadil Approved Drug Info Spodoptera frugiperda (Sf9) cells-MRP4 Km = 2.1 microM [3]
Cefadroxil Approved Drug Info Spodoptera frugiperda 21 (Sf21) cells-MRP4 Km = 0.25 microM [4]
Cefazolin Approved Drug Info Human embryonic kidney cells (HEK293)-MRP4 Km = 81 microM [4]
Ceftizoxime Approved Drug Info Human embryonic kidney cells (HEK293)-MRP4 Km = 18 microM [4]
Dinoprostone Approved Drug Info Spodoptera frugiperda (Sf9) cells-MRP4 Km = 3.4 microM [3]
Folic acid Approved Drug Info Spodoptera frugiperda (Sf9) cells-MRP4 Km = 170 microM [9]
Leucovorin Approved Drug Info Spodoptera frugiperda (Sf9) cells-MRP4 Km = 640 microM [9]
Methotrexate Approved Drug Info Human embryonic kidney cells (HEK293)-MRP4 Km = 220 microM [13]
Methotrexate Approved Drug Info Spodoptera frugiperda (Sf9) cells-MRP4 Km = 220 microM [9]
Methotrexate Approved Drug Info Spodoptera frugiperda (Sf9) cells-MRP4 Km = 1300 microM [22]
Olmesartan medoxomil Approved Drug Info LLC-PK1 cells-MRP4 Km = 26.2 microM [14]
Topotecan Approved Drug Info Human liver cancer cells (HepG2)-MRP4 Km = 1.66 microM [18]

 Withdrawn, Discontinued or Preclinical Drug

 Click to Show/Hide the Full List of Drug:            3 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
Aminohippuric acid Withdrawn Drug Info Spodoptera frugiperda (Sf9) cells-MRP4 Km = 160 microM [19]
Cyclic adenosine monophosphate Investigative Drug Info Spodoptera frugiperda (Sf9) cells-MRP4 Km = 44.5 microM [23]
Estradiol-17beta-glucuronide Investigative Drug Info Spodoptera frugiperda (Sf9) cells-MRP4 Km = 30.3 microM [23]
References
1 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
2 Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol. 2007 Feb;71(2):619-27.
3 The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9.
4 Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos. 2012 Mar;40(3):515-21.
5 Identification of the efflux transporter of the fluoroquinolone antibiotic ciprofloxacin in murine macrophages: studies with ciprofloxacin-resistant cells. Antimicrob Agents Chemother. 2009 Jun;53(6):2410-6.
6 Interaction of oxazaphosphorines with multidrug resistance-associated protein 4 (MRP4). AAPS J. 2010 Sep;12(3):300-8.
7 Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J. 2003 Apr 15;371(Pt 2):361-7.
8 ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology. 2009;9(1-2):136-44.
9 Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 2002 Jun 1;62(11):3144-50.
10 Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues. Biochem J. 2002 Feb 1;361(Pt 3):497-503.
11 P-glycoprotein, but not multidrug resistance protein 4, plays a role in the systemic clearance of irinotecan and SN-38 in mice. Drug Metab Lett. 2010 Dec;4(4):195-201.
12 Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. Blood. 2009 Aug 13;114(7):1383-6.
13 Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther. 2007 Jan;320(1):229-35.
14 Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos. 2007 Dec;35(12):2166-76.
15 Limited brain distribution of [3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), a pharmacologically active form of oseltamivir, by active efflux across the blood-brain barrier mediated by organic anion transporter 3 (Oat3/Slc22a8) and multidrug resistance-associated protein 4 (Mrp4/Abcc4). Drug Metab Dispos. 2009 Feb;37(2):315-21.
16 Fluo-cAMP is transported by multidrug resistance-associated protein isoform 4 in rat choroid plexus. J Neurochem. 2010 Oct;115(1):200-8.
17 Multidrug resistance protein 4 (MRP4/ABCC4) mediates efflux of bimane-glutathione. Int J Biochem Cell Biol. 2004 Feb;36(2):247-57.
18 Topotecan is a substrate for multidrug resistance associated protein 4. Curr Drug Metab. 2006 Jan;7(1):105-18.
19 Contribution of multidrug resistance protein 2 (MRP2/ABCC2) to the renal excretion of p-aminohippurate (PAH) and identification of MRP4 (ABCC4) as a novel PAH transporter. J Am Soc Nephrol. 2004 Nov;15(11):2828-35.
20 MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med. 1999 Sep;5(9):1048-51.
21 Transcriptomic analysis and plasma metabolomics in Aldh16a1-null mice reveals a potential role of ALDH16A1 in renal function. Chem Biol Interact. 2017 Oct 1;276:15-22.
22 The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol. 2002 Mar;13(3):595-603.
23 Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J Biol Chem. 2001 Sep 7;276(36):33747-54.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.